Cencora, Inc. (LON:0HF3)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 49.87B -6.1% |
| Revenue (ttm) | 254.14B +5.0% |
| Net Income | 2.62B +124.2% |
| EPS | 13.45 +125.5% |
| Shares Out | n/a |
| PE Ratio | 19.30 |
| Forward PE | 17.89 |
| Dividend | 1.99 (0.77%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 92 |
| Open | 349.63 |
| Previous Close | 346.79 |
| Day's Range | 343.48 - 349.63 |
| 52-Week Range | 245.77 - 381.28 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2026, Cencora's revenue was $337.40 billion, an increase of 5.00% compared to the previous year's $321.33 billion. Earnings were $3.48 billion, an increase of 124.16%.
Financial numbers in USD Financial StatementsNews
Cencora price target raised to $413 from $390 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Cencora (COR) to $413 from $390 and keeps an Overweight rating on the shares.
Cencora price target raised to $360 from $345 at BofA
BofA raised the firm’s price target on Cencora (COR) to $360 from $345 and keeps a Neutral rating on the shares.
Cencora price target raised to $380 from $350 at Evercore ISI
Evercore ISI raised the firm’s price target on Cencora (COR) to $380 from $350 and keeps an Outperform rating on the shares.
Cencora price target raised to $405 from $375 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Cencora (COR) to $405 from $375 and keeps an Outperform rating on the shares. The firm updated its model following…
Cencora Earnings Call Transcript: Q4 2026
FY2026 delivered 14% adjusted operating income growth and 12% adjusted EPS growth. FY2027 guidance implies 8%-10% EPS growth, while specialty remains the leading growth platform and portfolio changes weigh on headline growth.
Cencora Earnings release: Q4 2026
Cencora released its Q4 2026 earnings on November 4, 2026, summarizing the period's financial results.
Cencora Slides: Q4 2026
Cencora has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on November 4, 2026.
Cencora reports new organizational and reporting structure
Cencora (COR) announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. To better support its specialty provider and manufacturer partners and capit...
Cencora sees FY27 adjusted EPS $19.40-$19.75, consensus $19.76
The company is reaffirming its long-term growth target that contemplates adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%. Published first on…
Cencora reports Q4 adjusted EPS $4.66, consensus $4.57
Reports Q4 revenue $88.4B, consensus $87.91B. “Fiscal 2026 was a pivotal year for Cencora (COR), as we expanded our MSO platform through the acquisition of OneOncology, sharpened the focus of…
Cencora raises quarterly dividend 10% to 66c from 60c per share
On November 3, 2026, the company declared a quarterly dividend of 66c per common share, a 10%increase in its quarterly dividend rate from 60c per common share. The quarterly dividend…
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two yea...
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Reven...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC)
BALA CYNWYD, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Cencora price target raised to $377 from $346 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cencora (COR) to $377 from $346 and keeps an Overweight rating on the shares.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)
BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Cencora price target raised to $345 from $330 at BofA
BofA raised the firm’s price target on Cencora (COR) to $345 from $330 and keeps a Neutral rating on the shares after the company announced an agreement to acquire American…
Cencora sees FY26 adjusted EPS to be at least $17.90
Cencora (COR) last night updated its FY26 financial guidance to reflect the strength of the U.S. Healthcare Solutions reportable segment. Cencora now expects adjusted diluted earnings per share to be…
Cencora price target raised to $375 from $373 at Baird
Baird raised the firm’s price target on Cencora (COR) to $375 from $373 and keeps an Outperform rating on the shares. The firm updated its model following the sizable MSO…
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)
BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Cencora to acquire American Oncology Network in $2.4B transaction
Cencora (COR) has signed a definitive agreement to acquire American Oncology Network (AONC), a physician-led network of more than 350 oncology providers across 21 states. AON has built a physician-led...
Cencora to acquire American Oncology Network in $2.4 billion deal
Drug distributor Cencora said on Wednesday it would acquire American Oncology Network in a deal valuing the cancer care provider at up to $2.4 billion, deepening its reach in community oncology acro...
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), ...
Cencora price target raised to $380 from $340 at Argus
Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $380 from $340 and keeps a Buy rating on the shares. The firm sees sustainable earnings growth…
Cencora price target lowered to $400 from $430 at UBS
UBS lowered the firm’s price target on Cencora (COR) to $400 from $430 and keeps a Buy rating on the shares.